TriSalus Life Sciences, Inc. (TLSIW)
CIK 1826667 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 61.6M shares as of Aug 4, 2026 (10-Q).
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Private Warrants | 4.4M | not tagged | — | — |
| Public Warrants | 1.8M | $11.5 | 5y | — |
| Working Capital Warrants | 1.0M | not tagged | — | — |
| Orbi Med Warrants | 222,068 | not tagged | 7y | — |
| Initial Orbi Med Warrant | 130,805 | $8.1604 | — | FV $1.1M |
| Subsequent Orbi Med Warrants Entity One | 64,748 | not tagged | — | — |
| Subsequent Orbi Med Warrants Entity Two | 26,515 | not tagged | — | — |
| Subsequent Orbi Med Warrants | not tagged | $5.1556 | — | FV $500,000 |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 7.4M underlying shares, as reported Jun 30, 2026 (10-Q).
Reported exercise price: $11.5 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 69.0M = 61.6M O/S + 7.4M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 6, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 61.6M | Aug 4, 2026 |
| + Private Warrants (if exercised) | 4.4M | Jun 30, 2026 |
| + Public Warrants (if exercised) | 1.8M | Jun 30, 2026 |
| + Working Capital Warrants (if exercised) | 1.0M | Jun 30, 2026 |
| + Orbi Med Warrants (if exercised) | 222,068 | Jun 30, 2026 |
| + Initial Orbi Med Warrant (if exercised) | 130,805 | Apr 30, 2024 |
| + Subsequent Orbi Med Warrants Entity One (if exercised) | 64,748 | Feb 18, 2025 |
| + Subsequent Orbi Med Warrants Entity Two (if exercised) | 26,515 | Feb 18, 2025 |
| Fully diluted estimate | 69.2M | +12.4% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $150.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 3 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full TLSIW workspace